These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239 [TBL] [Abstract][Full Text] [Related]
5. Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. Chauffour A; Robert J; Veziris N; Aubry A; Pethe K; Jarlier V PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007857. PubMed ID: 32866170 [TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. Almeida DV; Converse PJ; Li SY; Tyagi S; Nuermberger EL; Grosset JH PLoS Negl Trop Dis; 2013; 7(2):e2085. PubMed ID: 23469308 [TBL] [Abstract][Full Text] [Related]
7. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131 [TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844 [TBL] [Abstract][Full Text] [Related]
9. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Ji B; Chauffour A; Robert J; Jarlier V Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. Converse PJ; Tyagi S; Xing Y; Li SY; Kishi Y; Adamson J; Nuermberger EL; Grosset JH PLoS Negl Trop Dis; 2015; 9(6):e0003823. PubMed ID: 26042792 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546 [TBL] [Abstract][Full Text] [Related]
12. Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice. Ji B; Chauffour A; Aubry A; Robert J; Ibrahim M; Jarlier V Antimicrob Agents Chemother; 2009 Jul; 53(7):2955-9. PubMed ID: 19364857 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518 [TBL] [Abstract][Full Text] [Related]
14. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Bentoucha A; Robert J; Dega H; Lounis N; Jarlier V; Grosset J Antimicrob Agents Chemother; 2001 Nov; 45(11):3109-12. PubMed ID: 11600364 [TBL] [Abstract][Full Text] [Related]